Inhibition of NF-κB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis

Jade Jaffar, Ian Glaspole, Karen Symons, Glen Westall

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease of unknown etiology and poor prognosis. In IPF, aberrant extracellular matrix production by activated, hyperproliferative fibroblasts drives disease progression but the exact mechanisms by which this occurs remains undefined. The transcription factor nuclear factor kappa-B (NF-ĸB) has been suggested as a potential therapeutic target in IPF and therefore the aim of this study was to investigate the efficacy of ACT001, an NF-ĸB inhibitor, on primary fibroblasts derived from patients with and without IPF. Primary lung fibroblasts derived from eight patients with IPF and eight age-matched non-diseased controls (NDC) were treated with 0–10 µM ACT001 and the effects on fibroblast activity (viability and proliferation, fibroblast-to-myofibroblast transition, fibronectin expression), interleukin (IL)-6 and IL-8 cytokine release were quantified. ACT001 inhibited fibroblast activity in a concentration-dependent manner in both groups of fibroblasts. ACT001 inhibited IL-6 but not IL-8 production in unstimulated fibroblasts. ACT001 is a water-soluble compound with a stable half-life in plasma, thus making it an attractive candidate for further investigation as a therapeutic in IPF. This study adds to the growing body of literature that demonstrates anti-fibrotic activity of NF-ĸB inhibition in the context of IPF.

Original languageEnglish
Article number111471
Number of pages9
JournalBiomedicine & Pharmacotherapy
Volume138
DOIs
Publication statusPublished - Jun 2021

Keywords

  • Fibroblasts
  • NF-ĸB
  • Pulmonary fibrosis

Cite this